缅北强奸

Le Groupe de recherche en sant茅 et droit de 缅北强奸 vous invite 脿 son troisi猫me s茅minaire de l'ann茅e universitaire, pr茅sent茅 par le professeur Yann Joly, DCL'09, directeur de recherche du Centre de g茅nomique et de politique (CGP) et professeur agr茅g茅 脿 la 贵补肠耻濒迟茅 de m茅decine de l'Universit茅 缅北强奸. Il nous parlera des d茅fis auxquelles les personnes intersexu茅es sont confront茅es en mati猫re d'acc猫s aux soins de sant茅.

Les places sont limit茅es. Pri猫re de confirmer sa pr茅sence aupr猫s de rghl.law [at] mcgill.ca.

Cette activit茅 est admissible pour 1,5 heures de formation continue obligatoire tel que d茅clar茅 par les membres du Barreau du Qu茅bec.

搁茅蝉耻尘茅

[En anglais seulement] About 1.7% of the Canadian population falls under the umbrella of 鈥渋ntersex鈥�, including sexual variation at the chromosomal, gonadal, hormonal, and genital levels. For intersex patients, healthcare is fraught with difficulties due to the various harms they suffer, including the concealment of medical information and trauma due to non-consensual pediatric surgical procedures.

In June 2017, three former US Surgeon Generals published a policy brief recognizing the psychosocial harms caused by the stigmatization of intersex individuals. Furthermore, in October 2017, the Parliamentary Assembly of the Council of Europe called for a ban on medically unnecessary "sex-normalizing" surgical interventions on intersex children. Unfortunately, intersex individuals still face serious human rights violations, discrimination, and stigmatization. Qualitative research, on which best practices and medical policies can be based to prevent these prejudices, remains underdeveloped. Additionally, there is presently a lack of Canadian-specific guidance or explicit legal protections to guide healthcare providers in their relationship with intersex patients.

This seminar will present the development of our project on access to healthcare for the intersex population in Qu茅bec and Canada, focusing on the following aspects: 1) presentation of the main objectives of the project; 2) challenges posed by research with the intersex community; 3) identification of foreign laws and policies of interest for the Canadian context; and 4) a description of the next steps to enable the development of public policies allowing better access to healthcare for this marginalized population.

Le conf茅rencier

[En anglais seulement] Yann Joly, Ph.D. (DCL), FCAHS, Ad.E., is the Research Director of the Centre of Genomics and Policy (), located inside the Genome Quebec Innovation Centre at 缅北强奸. He is also an Associate Professor at the Faculty of Medicine, Department of Human Genetics cross-appointed at the Bioethics Unit, at 缅北强奸. Professor Joly is a member of the Canadian Commission for UNESCO (CCU) Sectoral Commission for Natural, Social and Human Sciences. He is the current Chair of the Bioethics Workgroup of the International Human Epigenome Consortium (IHEC), and of the Ethics and Governance Committee of the International Cancer Genome Consortium (ICGC). He is also a member of the Human Genome Organization (HUGO) Committee on Ethics, Law and Society (CELS). Professor Joly鈥檚 research interests lie at the interface of the fields of scientific knowledge, health law (biotechnology and other emerging health technologies) and bioethics.